RESUMEN
We present a novel method for fabricating polarization-stable oxide-confined single-mode GaAs based vertical cavity surface emitting lasers (VCSELs) emitting at 850 nm using a new soft-lithography nano-imprint technique. A monolithic surface grating is etched in the output mirror of the laser cavity using a directly imprinted silica-based sol-gel imprint resist as an etch mask. The opto-electronic performance of these devices is compared to VCSELs fabricated by state-of-the-art electron-beam lithography. The lasers made using the soft nano-imprint technique show single-mode TM lasing at a threshold and laser slope similar to that of devices made by e-beam lithography. The soft nano-imprint technique also enables the fabrication of gratings with sub-wavelength pitch, which avoids diffraction losses in the laser cavity. The resulting single-mode VCSEL devices exhibit 29% enhanced efficiency compared to devices equipped with diffractive gratings.
RESUMEN
During the last 5 years the European Neuroendocrine Tumor Society (ENETS) has developed basic recommendations for a standardized pathological diagnosis and classification of neuroendocrine neoplasms (NEN) of the gastroenteropancreatic system. These were included in the novel classification of tumors of the digestive system by the World Health Organization (WHO 2010) and the TNM classification of the union for international cancer control (2009). This review presents the pathology diagnosis regarding (1) basic diagnosis, (2) clinically relevant optional diagnosis, (3) proliferation-based grading, (4) nomenclature and (5) TNM classification. It is emphasized that a standardized diagnosis of NEN, together with clinical and radiological findings, is crucial for prognostic stratification and optimal therapy of patients with NEN. Therefore a close interdisciplinary collaboration is essential.
Asunto(s)
Neoplasias del Sistema Digestivo/patología , Tumores Neuroendocrinos/patología , Biomarcadores de Tumor/análisis , Proliferación Celular , Neoplasias del Sistema Digestivo/clasificación , Neoplasias del Sistema Digestivo/cirugía , Humanos , Clasificación del Tumor , Estadificación de Neoplasias , Tumores Neuroendocrinos/clasificación , Tumores Neuroendocrinos/cirugía , Pronóstico , Terminología como AsuntoRESUMEN
Initiation of transcription from the cytRP promoter in Escherichia coli is activated by the cAMP-CRP complex and negatively regulated by the CytR repressor protein. By combining gel retardation and footprinting assays, we show that cAMP-CRP binds to a single site centered at position -64 and induces a considerable bend in the DNA. CytR binds to a region immediately downstream from, and partially overlapping, the CRP site, and induces a modest bend into the DNA. In combination, cAMP-CRP and CytR bind co-operatively to cytRP forming a nucleoprotein complex in which the proteins directly interact with each other and bind to the same face of the DNA helix. CytR binding concomitantly antagonizes the cAMP-CRP-induced bend. This study indicates that the minimal DNA region required to obtain CytR regulation consists of a single binding site for each of cAMP-CRP and CytR. The case described here, in which a protein-induced DNA bend is modulated by a second protein, may illustrate a mechanism that applies to other regulatory systems.
Asunto(s)
Proteínas Bacterianas/metabolismo , Proteínas Portadoras/metabolismo , Proteína Receptora de AMP Cíclico , AMP Cíclico/metabolismo , Escherichia coli/genética , Regiones Promotoras Genéticas , Receptores de AMP Cíclico/metabolismo , Proteínas Represoras/metabolismo , Proteínas Bacterianas/genética , Secuencia de Bases , Sitios de Unión , Proteínas Portadoras/antagonistas & inhibidores , AMP Cíclico/antagonistas & inhibidores , Citidina/metabolismo , ADN Bacteriano/química , ADN Bacteriano/metabolismo , Escherichia coli/metabolismo , Proteínas de Escherichia coli , Datos de Secuencia Molecular , Conformación de Ácido Nucleico , Unión Proteica , Receptores de AMP Cíclico/antagonistas & inhibidores , Proteínas Represoras/genéticaRESUMEN
The tsx-p2 promoter is one of at least seven Escherichia coli promoters that are activated by the cyclic AMP (cAMP)-cAMP receptor protein (CRP) complex and negatively regulated by the CytR repressor. DNase I footprinting assays were used to study the interactions of these regulatory proteins with the tsx-p2 promoter region and to characterize tsx-p2 regulatory mutants exhibiting an altered response to CytR. We show that the cAMP-CRP activator complex recognizes two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the -35 region, and a low-affinity site (CRP-2) is centered around position -74 bp. The CytR repressor protects a DNA segment that is located between the two CRP sites and partially overlaps the CRP-1 target. In combination, the cAMP-CRP and CytR proteins bind cooperatively to tsx-p2, and the nucleoprotein complex formed covers a region of 78 bp extending from the CRP-2 site close to the -10 region. The inducer for the CytR repressor, cytidine, does not prevent in vitro DNA binding of CytR, but releases the repressor from the nucleoprotein complex and leaves the cAMP-CRP activator bound to its two DNA targets. Thus, cytidine interferes with the cooperative DNA binding of cAMP-CRP and CytR to tsx-p2. We characterized four tsx-p2 mutants exhibiting a reduced response to CytR; three carried mutations in the CRP-2 site, and one carried a mutation in the region between CRP-1 and the -10 sequence. Formation of the cAMP-CRP-CytR DNA nucleoprotein complex in vitro was perturbed in each mutant. These data indicate that the CytR repressor relies on the presence of the cAMP-CRP activator complex to regulate tsx-p2 promoter activity and that the formation of an active repression complex requires the combined interactions of cAMP-CRP and CytR at tsx-p2.
Asunto(s)
Proteínas de la Membrana Bacteriana Externa/genética , Proteínas Bacterianas/metabolismo , Proteínas Portadoras/metabolismo , Proteína Receptora de AMP Cíclico , AMP Cíclico/metabolismo , Proteínas de Escherichia coli , Escherichia coli/genética , Regiones Promotoras Genéticas , Receptores de AMP Cíclico/metabolismo , Receptores Virales , Proteínas Represoras/metabolismo , Secuencia de Aminoácidos , Secuencia de Bases , Dermatoglifia del ADN , ADN Bacteriano/genética , ADN Bacteriano/metabolismo , Proteínas de Unión al ADN/metabolismo , Genes Bacterianos , Datos de Secuencia Molecular , Mutación , Plásmidos , ARN Bacteriano/análisis , Secuencias Reguladoras de Ácidos Nucleicos , Proteínas Represoras/genética , Proteínas Represoras/aislamiento & purificaciónRESUMEN
The Escherichia coli cytR-encoded repressor protein (CytR) controls the expression of several genes involved in nucleoside and deoxynucleoside uptake and metabolism. The cytR promoter was identified by determining the transcriptional initiation site of the cytR gene. A chromosomal cytR-lacZ+ operon fusion was isolated and used to study the regulation of cytR. We show that cytR expression is negatively controlled by the CytR protein and positively affected by the cAMP/CAP complex. Footprinting studies with purified CAP protein revealed two CAP binding sites upstream of the cytR promoter. A previously described mutation (cytR*) in the cloned cytR gene, which results in the phenotypic suppression of a CytR operator mutation in the tsx P2 promoter, was analysed. DNA sequence analysis of the cytR* mutation revealed a G-C to an A-T base pair transition at position -34 bp relative to the translational initiation site of cytR. This point mutation activates a cryptic promoter that is stronger than the wild-type cytR promoter and leads to overproduction of the CytR repressor.
Asunto(s)
Proteína Receptora de AMP Cíclico/farmacología , AMP Cíclico/farmacología , Escherichia coli/genética , Regiones Promotoras Genéticas , Proteínas Represoras/genética , Factores de Transcripción/genética , Transcripción Genética , Secuencia de Aminoácidos , Secuencia de Bases , Mapeo Cromosómico , Escherichia coli/efectos de los fármacos , Proteínas de Escherichia coli , Regulación Bacteriana de la Expresión Génica , Datos de Secuencia Molecular , Mutación , Proteínas Represoras/biosíntesis , Proteínas Represoras/sangreRESUMEN
An 11-yr-old captive-raised male woodchuck (Marmota monax) presented with ataxia, poor balance, left-sided weakness, circling to the left and nystagmus with the fast-phase directed towards the left. The clinical signs were compatible with a central vestibular deficit syndrome. Necropsy and histologic findings revealed a meningotheliomatous meningioma centered over the ventrolateral left pons and medulla along with acute bronchopneumonia, chronic glomerulopathy, interstitial nephritis, and phthisis bulbi.
Asunto(s)
Neoplasias Encefálicas/veterinaria , Marmota , Meningioma/veterinaria , Sciuridae , Envejecimiento , Animales , Neoplasias Encefálicas/complicaciones , Neoplasias Encefálicas/patología , Enfermedades Renales/complicaciones , Enfermedades Renales/veterinaria , Masculino , Meningioma/complicaciones , Meningioma/patologíaRESUMEN
The clinical response and pharmacokinetics of intravenous urapidil were studied in patients with uncontrolled severe hypertension. Six of nine patients achieved a diastolic blood pressure (DBP) of 100 mm Hg after initial administration of serial bolus doses and were then placed on maintenance infusions. Three of these six patients maintained a DBP 100 mm Hg or lower at infusion rates of 10 to 20 mg/hr, whereas the remaining three patients experienced a loss of DBP control despite rates of 40 mg/hr. Mean DBP was significantly reduced from 126 +/- 6 mm Hg (N = 9) to 105 +/- 15 mm Hg after the bolus phase (N = 9, P less than .05) and 99 +/- 18 mm Hg after the infusion phase (N = 6, P less than .05). Significant reductions in systolic blood pressure were also achieved after bolus and infusion phases. Adverse reactions included drowsiness, tachycardia, nausea and vomiting but were considered mild. Estimated pharmacokinetic parameters included Vz (0.80 +/- 0.20 L/kg), CL (2.53 +/- 0.99 mL/min/kg) and t1/2 (4.0 +/- 1.5 hr). Urapidil safely reduces blood pressure in patients with severe hypertension. An alternative dosing regimen is suggested.
Asunto(s)
Antihipertensivos/farmacología , Hipertensión/tratamiento farmacológico , Piperazinas/farmacología , Adolescente , Adulto , Anciano , Antihipertensivos/administración & dosificación , Antihipertensivos/farmacocinética , Presión Sanguínea/efectos de los fármacos , Femenino , Humanos , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Piperazinas/efectos adversos , Piperazinas/farmacocinéticaRESUMEN
The Escherichia coli tsx gene encodes an outer membrane protein that is involved in nucleoside uptake and serves as the receptor protein for colicin K and several bacteriophages. Regulation of its expression was studied by using tsx-lacZ protein and operon fusion strains carrying mutations in deoR, cytR, and crp. The cytR-encoded repressor had a stronger influence on tsx transcription than the DeoR repressor did, and the level of tsx expression in a deoR cytR double mutant was approximately the sum of those found in the single deoR and cytR strains. This double negative control of Tsx synthesis was superceded by a positive control mechanism mediated by the cyclic AMP-catabolite activator protein (cAMP-CAP) complex. Our results suggest that tsx expression is controlled at two separate and differently regulated promoters: the weaker promoter (P1) is repressible by DeoR, while the stronger promoter (P2) is subject to negative and positive control by the CytR repressor and the cAMP-CAP complex, respectively. A mutant was isolated that showed unaltered tsx regulation by DeoR and the cAMP-CAP complex but strongly reduced repression by CytR. This tsx operator mutant was used to obtain a suppressor mutation located on a plasmid carrying the cloned cytR gene that restored CytR control of tsx expression. The direction of tsx transcription was determined and found to be counterclockwise on the E. coli chromosome.
Asunto(s)
Proteínas de la Membrana Bacteriana Externa/genética , Escherichia coli/genética , Regulación de la Expresión Génica , Factores de Transcripción/fisiología , Proteínas de la Membrana Bacteriana Externa/biosíntesis , Clonación Molecular , Proteína Receptora de AMP Cíclico/fisiología , Escherichia coli/metabolismo , Genes Bacterianos , Mutación , Regiones Operadoras Genéticas , Regiones Promotoras Genéticas , Proteínas Represoras/fisiología , Supresión Genética , Transcripción GenéticaRESUMEN
Valvular heart disease is a recognized feature of the connective tissue diseases. It occurs to a variable extent in osteogenesis imperfecta and frequently involves the aortic valve. Replacement of the aortic valve, although required, may be complicated by bleeding problems secondary to platelet dysfunction and capillary fragility. A successful aortic valve replacement in a patient with type I osteogenesis imperfecta is described with special reference to hematologic manipulations to control bleeding post-operatively.
Asunto(s)
Válvula Aórtica/cirugía , Prótesis Valvulares Cardíacas , Osteogénesis Imperfecta/complicaciones , Adulto , Válvula Aórtica/patología , Válvula Aórtica/fisiopatología , Transfusión Sanguínea , Drenaje , Ecocardiografía , Humanos , Masculino , Osteogénesis Imperfecta/cirugíaRESUMEN
Both octopamine and proctolin potentiate nerve-evoked skeletal muscle contractions in the horseshoe crab, Limulus. The threshold concentration for octopamine was 10(-9) to 10(-8)M, while for proctolin it was 3 X 10(-9)M. Norepinephrine and dopamine produced effects similar to octopamine but at higher thresholds; tyramine and serotonin were ineffective. Octopamine caused significant increases in amplitudes of excitatory postsynaptic potentials (epsps) of muscle fibers, but had little effect on muscle fiber input resistance or membrane potential. Also, octopamine did not affect depolarization of muscle fibers and subsequent contraction due to the direct action of exogenously applied glutamate. These results suggest that octopamine potentiates nerve-evoked contractions primarily by facilitating release of neuromuscular transmitter. At concentrations above 10(-7)M, however, octopamine sometimes caused muscle spikes in response to motoneuron stimulation, a finding that suggests that octopamine may also have some postsynaptic action. Proctolin potentiated the muscle contractions evoked by glutamate but had little effect on glutamate-evoked muscle fiber depolarization, muscle fiber input resistance, or membrane potential. Thus, proctolin appears to act directly on skeletal muscle to enhance contractility. The proctolin-induced potentiations of contraction were sometimes accompanied by modest increases in epsp amplitude, so that unlike lobster skeletal and Limulus cardiac neuromuscular preparations, proctolin may have a secondary direct synaptic effect. Both octopamine and proctolin have been found in Limulus cardiac ganglion. This potential access to the hemolymph and the relatively low threshold concentrations needed for physiological action suggest that octopamine and proctolin could function as hormonal modulators of neuromuscular function in Limulus.